Reduced stress-induced anxiety/depression-like behaviors, inhibited stress-induced NF-κB activation and NF-κB+/IBA1+ cell count, and reduced anxiety/depression and colitis by modulating NF-κB-mediated expression of brain-derived neurotrophic factors and dysregulation of intestinal flora. Here, AIF1 is linked to depressive symptom measurement.